Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program

Skye Bioscience Inc

Skye Bioscience CEO Punit Dhillon joined Steve Darling from Proactive to share news announcing the company's uplisting of its common stock to the Nasdaq stock exchange, trading under the ticker symbol "SKYE." This achievement signifies a significant milestone for the company, reflecting advancements in its Phase 2 clinical programs, financial position, and shareholder base. Dhillon further disclosed that Skye Bioscience reached another critical milestone by successfully dosing 56 patients with SBI-100 Ophthalmic Emulsion in its Phase 2a study and completing final study visits for all participants. SBI-100 OE, a cannabinoid receptor type 1 agonist administered topically to the eye, is designed to address the unmet needs of patients with elevated intraocular pressure related to primary open-angle glaucoma or ocular hypertension. Notably, all treated patients completed the study without early discontinuations due to adverse events, demonstrating the safety profile of SBI-100 OE. The company anticipates releasing topline data for the entire study in the second quarter, marking a significant milestone in advancing its clinical program. Skye Bioscience's move to the Nasdaq exchange underscores its commitment to enhancing visibility, expanding its investor base, and unlocking value for shareholders as it progresses in its mission to develop innovative therapies for ocular diseases. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

May 07, 2024 11:59 AM Eastern Daylight Time

Video

Shedding Light on Cystic Fibrosis Awareness Month

YourUpdateTV

Cystic fibrosis (CF) is a rare, progressive, and genetic disease that currently affects about 40,000 people in the United States. CF is the result of a defective gene, inherited from each parent, and the disease can impact people of all races and ethnicities. Recently, KC White, Board Chair of the Cystic Fibrosis Foundation, participated in a nationwide satellite media tour to discuss the disease, her personal journey, and how the Foundation is helping progress care and treatment options. A video accompanying this announcement is available at: https://youtu.be/8wj8u0JEqLU CF is a life-shortening disease that prevents our bodies from clearing mucus. This can lead to lung infections, poor nutrition, lung disease, and a host of unique challenges that can impact every aspect of a person’s life. When it was first discovered, it was considered a fatal pediatric disease. But due to transformative advancements in treatments and high-quality care, the life-expectancy for someone born with CF today is 56. While that number is climbing there is still a long way to go and unfortunately, not all people with CF equally benefit from this progress. KC White was elected chair of the Cystic Fibrosis Foundation’s Board of Trustees in 2022 after serving on the Board since 2005. Diagnosed with cystic fibrosis at age 3, White has been a committed volunteer and inspiring advocate for the Foundation since childhood and is the first person with CF to serve as board chair. When she was diagnosed, she wasn’t expected to live past high school age, but her family refused to accept that fate, which prompted their dedication to the Foundation’s work. Because of recent treatments known as modulators, about 90% of the CF population (including KC) experienced an incredible transformation in their health. With this though, comes navigating unplanned challenges including careers, finances, family, and more. In addition to fueling the research, particularly in genetic therapies, that will lead to transformative treatments for the entire CF population, the CF Foundation works to support the CF community in all aspects of their lives through support programs and fostering connection opportunities. Every May, the cystic fibrosis community comes together for CF Awareness Month to educate the public about the rare disease, share personal stories, and encourage people to get involved and unite behind a shared mission: finding a cure for all people with CF. The CF Foundation is committed to finding a cure and providing all people with CF the opportunity to lead long, fulfilling lives. The Foundation is aggressively funding research and drug development, advancing high-quality, specialized care, and partnering with and advocating for the CF community. For more information, visit CFF.ORG/CFMONTH About KC White KC White was elected chair of the Cystic Fibrosis Foundation’s Board of Trustees in 2022 after serving on the Board since 2005. Diagnosed with cystic fibrosis at age 3, White has been a committed volunteer and inspiring advocate for the Foundation since childhood, speaking at her first Foundation event when she was only 9 years old. She is the first person with CF to serve as board chair. White received her Master of Applied Positive Psychology from the University of Pennsylvania in 2022 and currently serves as an assistant instructor in the program. She is also the Head Varsity Women’s Lacrosse coach for the Chagrin Falls, Ohio, Tigers. She and her husband, Justin, have one son, Mac. About the Cystic Fibrosis Foundation The Cystic Fibrosis Foundation is a donor-supported nonprofit organization leading the relentless pursuit of a cure for cystic fibrosis. The Foundation is committed to providing all people with CF the opportunity to lead long, fulfilling lives by funding research and drug development, advancing high-quality, specialized care, and partnering with and advocating for the CF community. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. The organization supports and accredits a national network of over 130 CF care centers recognized by the National Institutes of Health as a model of care for a chronic disease. Also, the Foundation manages support programs and fosters connection opportunities for the CF community. Based in Bethesda, Md., the Foundation’s impact is made possible by the work of nearly 70 local chapters across the country. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 07, 2024 09:23 AM Eastern Daylight Time

Video

InMed (NASDAQ: INM) Developing Cannabinoids Analogs To Treat Alzheimer's – New Studies Showcase INM-901's Therapeutic Abilities

Benzinga

By Meg Flippin, Benzinga Whether due to an aging population or overall population growth, cases of Alzheimer's are increasing. As it stands, nearly seven million Americans suffer from this disease that attacks memory and cognitive functions. By 2050, that’s forecast to reach close to 13 million people. The costs associated with treating Alzheimer's and dementia are projected to swell to $1 trillion by 2050 from $360 billion today. Alzheimer’s is the fifth leading cause of death for people 65 and older. There are several treatments on the market, but they focus on addressing the symptoms rather than repairing and regenerating the damaged neurons. Some drugs and treatments may slow the progression of cognitive decline, but none can reverse the effects of Alzheimer’s. That may change thanks to companies like InMed Pharmaceuticals Inc. (NASDAQ: INM). The leader in cannabinoid and cannabinoid analogs pharmaceutical research, development, manufacturing and commercialization has identified a rare cannabinoid to treat Alzheimer’s. Named INM-901 and based on early preclinical research, the cannabinoid analog showed potential to target several biological pathways associated with Alzheimer’s, providing neuroprotection to the brain neurons and improving neuronal function. Fighting Alzheimer’s With Cannabinoids Recent in vivo studies have shown that INM-901 can improve cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function. INM-901 also displayed neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study. Most recently, the company announced additional preclinical data demonstrating INM-901’s positive pharmacological effects. Several preclinical studies that were conducted in well-characterized Alzheimer’s models demonstrated that INM-901 was able to reduce neuroinflammation and improve neuronal function. The company said the studies also supported the observations made in previously released behavior studies in which locomotor activity, cognition and memory were improved. As a result of these studies, InMed said it plans to accelerate the development of its Alzheimer’s program. Currently, long-term behavioral and mechanism of action / receptor interaction studies are underway with data read-out expected in the third quarter. Meanwhile, InMed said the development of the chemistry, manufacturing and controls (CMC) for drug substance and oral drug product formulation are on-going. “The recent results demonstrating pharmacological effects in in vivo disease models continue to validate INM-901 as a potential treatment of AD,” said Dr. Eric Hsu, Senior Vice President of Preclinical Research and Development at InMed. “There continues to be a major unmet medical need for this multi-factorial disease and differentiated therapeutic mechanisms may play an important role. We believe the development of INM-901 may address several pathological factors including neuroinflammation, neuroprotection and neuritogenesis.” Multiple Mechanisms Of Action InMed said it is particularly encouraged that INM-901 has multiple potential ways of impacting the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors and the peroxisome proliferator-activated receptor (PPAR) signaling pathway. CB1 and CB2 receptors are part of the endocannabinoid system and are found throughout the body, including in the brain. CB1 receptors are primarily located in the central nervous system, particularly in areas involved in memory, cognition and motor function. CB2 receptors are involved in modulating neuroinflammation and immune responses. Activation of CB1 and CB2 receptors has been shown to help protect brain cells from damage and death. In Alzheimer’s where neuronal death is a hallmark feature, enhancing the activity of these receptors may help to slow down the progression of the disease, reports InMed. Activation of these receptors and other cellular receptors has also been shown to have an impact on neuroinflammation, which is believed to contribute to the progression of Alzheimer’s. As a result, InMed believes INM-901 could offer novel therapeutic strategies for the treatment of this devastating condition. Adding To Its Expertise To further develop INM-901, InMed is deepening its pedigree, and it recently added Dr. David G. Morgan, a renowned leader in neurodegenerative disease, to its Scientific Advisory Board. This reinforces InMed’s commitment to advancing its INM-901 program for the treatment of Alzheimer’s disease. Morgan is the director of the Alzheimer’s Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. His research interests are Alzheimer’s disease, aging and brain function. He is internationally recognized for his work on immunotherapy and gene therapy to treat Alzheimer-related pathologies. “We are privileged to welcome someone of Dr. Morgan’s stature to our SAB, which underscores the recent progress we’ve achieved in the INM-901 program. Dr. Morgan’s significant contributions and pioneering breakthroughs have made him a leading authority in Alzheimer’s research. His guidance and expertise will be invaluable as we advance to the next stages of development of our INM-901 program in the treatment of Alzheimer’s,” said Hsu. The number of Alzheimer’s cases is set to soar in the years to come as the population ages. InMed wants to slow that, and is betting INM-901 can help. So far studies are backing that up, with more data to come this year. Featured photo by Natasha Connell on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 07, 2024 09:00 AM Eastern Daylight Time

Image

New Study Shows Cardio Diagnostics’ (NASDAQ: CDIO) PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more precise, has announced the publication of results from a budget impact modeling study for one of its leading clinical products. PrecisionCHD is an integrated genetic-epigenetic test for the detection of coronary heart disease (CHD). The peer-reviewed study, The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs, highlights the test’s promising developments. The study’s PrecisionCHD budget impact model was designed to evaluate the cost savings associated with using PrecisionCHD as the primary method of initial CHD assessment in place of current commonly used tests, including exercise electrocardiograms, coronary computed tomography angiography (CCTA) and angiograms. It considered factors such as the number of tests performed, the cost of each test and the impact of test results on treatment decisions. The results suggest that using PrecisionCHD could lead to significant cost savings for patients, with an estimated $113.6 million saved per year for a plan with one million members. These savings are primarily driven by the lower cost of PrecisionCHD compared to traditional tests, along with the reduced need for additional testing. Further, the model found that cost savings were not sensitive to patient demographics or insurance plan design. Similar results were observed for plans that exclude Medicare enrollees, only include Medicare enrollees (Part B or Medicare Advantage), offer large co-insurance rates and charge larger co-pays. PrecisionCHD is a multiomic DNA test that aids in the detection of stable CHD. The test evaluates six DNA methylation and ten genetic biomarkers and uses a proprietary machine learning model to interpret the genetically contextual methylation signals from these biomarkers. The sensitivity and specificity of this test are 79% and 76%, respectively, with the clinical validation study in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics being recently published in the Journal of American Heart Association. “The data from this study suggests that the broader use of PrecisionCHD as the initial test for detecting coronary heart disease can yield significant savings to payers,” said David Frisvold, PhD, Associate Professor in the Department of Economics at the University of Iowa and lead author of this study. “More importantly, the reported cost savings were shown to be generalizable to various health plans, potentially leading to increased access to care and improved outcomes for patients with CHD.” PrecisionCHD was recently awarded the Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code, 0449U, by the American Medical Association. It became effective on April 1, 2024. PrecisionCHD was also awarded the Innovation Technology contract from Vizient, the United States’ largest group purchasing organization, whose customer base encompasses over 60% of hospitals and 97% of academic medical centers in the country. Increasing Access, Reducing Costs Heart disease remains the leading cause of death among Americans. It is also one of the largest cost centers for payers. If the barriers to obtaining early cardiovascular care persist, the prevalence and costs associated with heart disease will likely increase. Currently, exercise electrocardiogram, CCTA and single photon emission computed tomography (SPECT) are among the initial tests used to diagnose CHD. These tests are resource-intensive, and require expensive infrastructure and specialized personnel, creating inherent barriers to broader adoption, especially in rural America. The continued reliance on these tests as the initial testing mode for CHD diagnosis could lead to higher costs for payers. Some of the current tests also involve risks that are associated with being exposed to radiation and contrast dyes that could affect the health of the patient long term. Cardio Diagnostics says that PrecisionCHD, on the other hand, is a more cost-efficient, highly scalable and less resource-intensive alternative for initial CHD detection testing. Its sensitive and specific performance minimizes the likelihood of false positives and negatives, potentially decreasing the need for costly follow-up tests and procedures. Furthermore, PrecisionCHD can be implemented virtually via telemedicine and at-home for blood sample collection. It can also be deployed in community settings via mobile health clinics as well as in a more traditional provider setting.This multimodal delivery approach means greater access for patients, and Cardio Diagnostics expects potential additional cost savings for payers as well, with earlier detection and management of CHD. “We believe that PrecisionCHD has the potential to revolutionize how coronary heart disease is diagnosed and managed,” said Robert Philibert, MD, PhD, Chief Medical Officer and co-founder of Cardio Diagnostics, and the senior author of the study. “We are confident that PrecisionCHD will drive value for many healthcare stakeholders including the patient, provider and payer.” Optimizing Cost Efficiency Health plans increasingly prioritize precision medicine solutions to enhance patient outcomes and optimize cost-efficiency, reflecting an industry-wide transition from personalized to precision medicine. This evolution is underpinned by integrating genomic, clinical and socio-economic data, enabling healthcare providers to customize treatment approaches and advance therapeutic innovation. Similarly, provider-led health plans face the same challenges in optimizing patient care while reducing unnecessary medical spending. PrecisionCHD stands out as a resource for health insurers and healthcare providers aiming to streamline the management and financial burden of CHD. As health systems increasingly adopt value-based care (VBC) models, the focus is increasingly on achieving superior patient outcomes and improved population health while maintaining cost-effectiveness. Throughout last year, the expansion and refinement of VBC models have underscored a concerted effort among healthcare providers, payers and policymakers to enhance patient care and manage expenses effectively. This strategic alignment with VBC frameworks highlights the significant role of tools like PrecisionCHD. These tools support targeted, data-driven decisions in CHD treatment and management, potentially revolutionizing approaches to healthcare delivery and cost management. Featured photo by Testalize.me on Unsplash Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

May 07, 2024 08:45 AM Eastern Daylight Time

Image

Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection

Benzinga

By James Blacker, Benzinga Despite the large numbers of people affected, cancer treatments have largely produced unsatisfactory results to curb the rise in cases. According to the American Cancer Society, more than 2 million new cancer cases are projected to be diagnosed in the United States in 2024, with over 600,000 cancer deaths expected to occur. Cancer is already the second-leading cause of death in the U.S. overall and the leading cause among people under 85, and analysis from Yale Medicine indicates that new cases of cancer are ticking upward. It’s clear the disease remains a formidable challenge, which is driving companies such as California-based biotechnology firm Renovaro Inc. (NASDAQ: RENB) to pioneer groundbreaking solutions to revolutionize diagnostics and offer more efficient treatment. Renovaro’s Mission To Advance Cancer Care Renovaro is on a mission to accelerate precision and offer personalized medicine for longevity. It leverages AI and biotechnology platforms to enable early diagnosis, better-targeted treatments and drug discovery. The company comprises a biotech arm, RenovaroBio, which focuses on advanced cell-gene immunotherapy, and an AI arm, RenovaroCube, which is committed to the early detection of cancer, its recurrence and subsequent treatment. Alliances With Industry Leaders What makes Renovaro’s approach so unique is its AI platform for diagnosis, which was made possible thanks to a strategic alliance with Nvidia Corp. (NASDAQ: NVDA). In August 2023 Renovaro announced its alliance with Nvidia’s Inception program, which allows it to deploy next-generation AI running on Nvidia’s latest chips for greater accuracy in cancer detection. Renovaro also announced in April that it plans to acquire 100% of Dutch health-tech firm Cyclomics, amending its initial agreement to acquire 75% of the company. Once the acquisition is complete, Renovaro will be able to use Cyclomics’ 4 th generation molecular technology, developed in partnership with Oxford Nanopore Technologies PLC (LON: ONT), to identify single cancer DNA molecules from a single vial of blood with nearly 100% accuracy. Introducing Flamingo: A Game-Changer In Multi-Cancer Detection Also in April this year, Renovaro unveiled Flamingo, “a potentially groundbreaking multi-cancer detection model,” according to the company. Flamingo leverages ultra-low pass whole genome sequencing of cell-free DNA (cfDNA), allowing early detection of cancers. While traditional cancer detection methods can fail to identify cancer at an early stage – when treatment is most effective – Flamingo harnesses the power of AI to perform highly accurate analysis of minute amounts of cfDNA data to distinguish cancer from healthy samples. Ultimately, this potentially allows cancer interventions to happen earlier and improves patient outcomes. “[Flamingo] will accelerate our efforts to realize a paradigm shift in cancer detection,” shares RenovaroCube CTO Frank van Asch. “With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 07, 2024 08:25 AM Eastern Daylight Time

Image

American Aires Inc. Executing a Strategy To Increase Exposure And Drive Sales

AAIRF, EDR, FOX, RUM

In our modern, technologically driven world, the proliferation of electronic devices emitting electromagnetic fields (EMFs) has raised significant concerns. While these EMFs have undoubtedly improved our lives in terms of convenience and connectivity, they also pose unintended health consequences. Scientific studies have shown that EMF radiation exposure can lead to brain inflammation, tissue damage, and the development of various diseases, including neurodegenerative conditions. This correlation between brain electrical activity and cognitive function underscores the potential risks of prolonged EMF exposure. Pioneering Protection Canadian-based nanotechnology company American Aires Inc. (CSE: WIFI) (OTC: AAIRF) has emerged as a pioneer in addressing the harmful effects of EMF radiation. With over 20 years of dedication and at least $20 million invested in research and development, American Aires has developed cutting-edge solutions to mitigate EMF exposure and optimize human health. The cornerstone of American Aires' technology is its proprietary silicon-based resonator, designed to protect against EMF radiation. Unlike traditional methods that aim to block or absorb radiation, American Aires' technology actively modulates EMFs, creating a protective barrier around electronic devices. These sleek and stylish devices provide personal and area protection without the need for a power source, targeting EMR emitted by various consumer electronic devices, including cellphones, computers, baby monitors, and Wi-Fi, including high-speed 5G networks. Scientific Validation The effectiveness of American Aires' microchip in reducing the harmful effects of EMF radiation has been reaffirmed by the scientific community. A recently published study in the Link Journal confirmed the chip's stabilizing capabilities, supported by eight peer-reviewed studies and 25 clinical and scientific reports, validating the technology. This scientific validation underscores the credibility and reliability of American Aires' solutions in the EMF protection space. Recent Exposure American Aires Inc. (OTC: AAIRF) (CSE: WIFI) American Aires has effectively prioritized public education and brand exposure, recognizing the pivotal role they play in expanding its market presence. CEO Josh Bruni's recent appearance on the Fox News Buiness Channel national TV series "Health Uncensored with Dr. Drew" on May 5, 2024, signifies a significant milestone for the company. This appearance provided a substantial platform for American Aires to showcase its innovative solutions to a vast audience. Broadcasting on a reputable network like Fox News (NASDAQ: FOX), which reaches hundreds of millions of households across the nation, underscores the magnitude of this opportunity. By featuring on such a prominent platform, AAIRF aimed to not only educate viewers about the importance of safeguarding against electromagnetic radiation but also to significantly raise awareness about the company and its mission. CEO Josh Bruni's presence on the program further solidified the company's commitment to transparency, education, and promoting awareness of its groundbreaking technology. To watch the segment and learn more about American Aires' innovative solutions, click here. Additionally, AAIRF has expanded its reach through a series of impactful partnerships and alliances. In a recent collaboration with Endeavor Group Holdings (NYSE: EDR ) subsidiary William Morris Endeavor Entertainment (WME), a powerhouse in the entertainment, sports, and fashion industries, American Aires aims to amplify its brand presence and extend its reach. This partnership promises to spotlight the manifold benefits of Aires' wellness and performance optimization solutions, leveraging WME's extensive network of top-tier artists, athletes, and content creators. The company's #airesathletes campaign further demonstrates its commitment to widening and deepening relationships with top athletes and celebrities. Partnering with renowned figures like Tiki Barber, the former NFL running back, American Aires showcases how its technology benefits athletes and consumers alike, promoting optimal performance and rapid recovery. Continuing its trajectory of strategic exposure, AAIRF announced a pivotal collaboration with Rumble Inc. (NASDAQ: RUM), a leading social video platform with a global reach. This partnership builds upon the company's ongoing efforts to amplify its brand presence and reach a wider audience. The groundwork for the Rumble partnership began over the past year, with AAIRF and RUM working together to test the traffic and conversion performance of the video platform. This collaboration paved the way for American Aires to officially launch a pilot test consisting of a paid ad campaign on Rumble. As part of this campaign, one of Rumble's most popular influencers, English comedian, actor, and influencer Russell Brand, with 1.87 million followers on the platform, will read one Aires ad per week over multiple episodes of his show on Rumble. Additionally, Rumble will display pre-roll "run of network" ad placements before or after Brand's shows air during the campaign. Commenting on the significance of this collaboration, American Aires CEO Josh Bruni stated, "It's very significant that this test campaign features Russell Brand. He not only aligns well with the Aires brand but also has a growing global audience through Rumble and across other media platforms that can reach potential Aires customers around the world." Financial Performance American Aires Inc. (OTC: AAIRF) has experienced robust revenue growth, doubling its revenue consistently over the past two years. In the first nine months of 2022 alone, the company generated $5.5 million in revenue, representing a 63% year-over-year increase. With extrapolated growth, American Aires could potentially achieve $10 million in sales in 2023. Moreover, AAIRF boasts superior profit margins, with gross margins averaging about 60%, rivaling top technology companies like Nvidia and Apple. The company reached a significant milestone by achieving positive adjusted EBITDA in its most recent quarter, highlighting its financial strength and growth potential. Furthermore, American Aires continues to demonstrate its industry leadership with recent announcements. The company achieved record Q4 and annual 2023 order volume, coupled with significant EBITDA profitability in Q4. This financial success reflects American Aires' sustained growth trajectory and its commitment to delivering value to shareholders. American Aires Inc. (OTC: AAIRF) (CSE: WIFI) stands at the forefront of the EMF protection and human optimization industries, offering innovative solutions to address the growing concerns surrounding electromagnetic radiation. Recent advancements, strong financial results, partnerships, and scientific validation of its patented technology all contribute to American Aires reaffirming its leadership in enhancing human well-being in a technology-driven world. As the company continues to innovate and expand its reach, it remains a stock to watch for any smart investor. For more information https://airestech.com/ Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained by Clarkham Capital International to assist in the production and distribution of content related to AAIRF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://RazorPitch.com

May 07, 2024 07:00 AM Eastern Daylight Time

Image

Older Americans Are Facing a Loneliness Crisis:

YourUpdateTV

Media tour conducted to discuss how AmeriCorps Seniors can help by fostering connections and providing purpose. A video accompanying this announcement is available at: https://youtu.be/dcH7-VsQaYQ Older adults are especially vulnerable to loneliness and social isolation, which can have a serious effect on health, according to a recent report issued by the U.S. Surgeon General. Chronic loneliness (persistent feelings of isolation and/or a lack of companionship) can adversely affect mental, cognitive, and physical health, general well-being and even longevity. However, there are ways to overcome loneliness and volunteering might be the answer. AmeriCorps Seniors is helping older adults form connections in their community, provide purpose and improve their lives through volunteering. After two years of volunteering with AmeriCorps Seniors, 78% of those who reported more than five symptoms of depression at the beginning of the study said that they felt less depressed two years later. 88% of those who first described a lack of companionship said they felt less isolated after two years. AmeriCorps is the federal agency for national service and volunteerism. AmeriCorps Seniors focuses on engaging adults ages 55 and up in service in their local communities. Through three signature programs, R-S-V-P, the Foster Grandparent Program and the Senior Companion Program, AmeriCorps Seniors provides a space for older adults to take charge of this moment in life and use their time in impactful ways. Each year, AmeriCorps Seniors matches more than ONE HUNDRED FORTY THOUSAND Americans with service opportunities. For example, Shelley Brosnan, a volunteer with AmeriCorps Seniors RSVP through Volunteer Fairfax, Fairfax, Va., said, “Giving back is so very important. I’ve been volunteering for most of my adult life. Volunteering allows me to connect with my community and make it a better place. I also love the social aspects and meeting people who share my interests. We have a chance to help others and form new relationships, which has grown my social circle.” RSVP offers flexible scheduling and a diverse mix of opportunities. The Foster Grandparent Program pairs volunteers with children and youth in mentoring and tutoring relationships. Lastly, the Senior Companion Program provides a helping hand to other older adults and those with disabilities. They also support caregivers through respite services. For more information and to find volunteer opportunities near you, visit AMERICORPS.GOV/YOURMOMENT. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 03, 2024 01:01 PM Eastern Daylight Time

Video

How Can Small Investors Access Private Deals With Big Potential?

OurCrowd

By MATTHEW KALMAN OurCrowd allows investors to stake a claim in promising startups for as little as $10,000 “Stripe, a payments startup, is one of the most successful companies to emerge from Silicon Valley in a generation. Last year, it hit a valuation of $65 billion. But in the 15 years since it was founded, there has not been a way for most individuals to invest in it,” Erin Griffith reported in The New York Times in April. “It is a problem that has vexed retail investors for years, as startups like Stripe, SpaceX and OpenAI soar to enormous valuations in the private market,” Griffith says. “By the time the companies go public a decade or more after they started, their growth has often slowed and their valuations are high.” Even if you can access such deals, the minimum investment is “often very high,” James Seyffart, a research analyst at Bloomberg Intelligence, tells Griffith. One rare access point for such private deals is OurCrowd, a global investment platform that has introduced its worldwide community of over 235,000 accredited investors to opportunities in more than 460 portfolio companies, attracting over $2.3 billion in commitments to date. The minimum investment in a single startup deal through OurCrowd can be as little as $10,000. <iframe width="560" height="315" src= https://www.youtube.com/embed/MOoAs0m2JRE?si=qS2U_CDdsArdnTip title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe> The definition of “accredited investor” varies, depending on your jurisdiction. In the U.S., the SEC sets the bar at someone with an annual income of at least $200,000, or a net worth of $1 million or more. That’s because investing in startups is a high-return, high-risk business and investors must be wealthy and sophisticated enough to realize what they are getting into. Startup companies seeking private investment generally prefer to attract VCs, institutions, pension funds and high net worth individuals who can commit at least six-figure sums. This keeps the company’s cap table clean, allowing its executives to concentrate on building their business instead of fielding phone calls from dozens of retail investors. The result: thousands of would-be investors are locked out of opportunities where startups can sometimes grow by 50x or 100x. Extending Access The OurCrowd model blows open this exclusive club, extending access to these potential blockbuster deals to thousands of investors for whom a $100,000 investment in a single company is too high, but $10,000 is attractive. “OurCrowd is enabling hundreds of thousands of investors around the world to access the exciting venture capital asset class,” says Jon Medved, OurCrowd’s founder and CEO. “It turns out that if you want to make real money today, you have to invest in startup companies before they go public. In the good old days, you could have invested in something like Amazon or Microsoft, held it from an IPO and made thousands of times your money. But today that's not possible because the private companies are going public much later.” “The smart money, the smart investor, wants to find a way to get into these exciting dynamic growth stories while they're still private,” Medved says. While SpaceX did not appear on the OurCrowd platform, members have invested in Axiom Space, selected by NASA to build the successor to the International Space Station and NASA’s new generation of space suits; Stoke Space, which is developing reusable rockets for daily launch missions; ICON, which is creating 3D-printed housing for use on the Moon; and Ursa Major, America’s only independent provider of aerospace propulsion engines for the commercial space, hypersonic and defense launch markets. Likewise, OpenAI is not available via OurCrowd, but other promising AI companies have recently attracted millions of dollars of investment and, for investors wishing to further diversify, OurCrowd also offers a dedicated AI Fund. “It’s traditionally very hard for accredited investors and even family offices to invest in individual startup investment opportunities,” says Lisa Graston, OurCrowd’s associate director for Investor Relations. “You can invest via a VC fund, but then you’re relinquishing control and you’re dependent on the fund managers.” “Historically, the VC asset class has outperformed the public markets and it’s an asset class that’s really difficult to access. We are really democratizing the space,” Graston adds. To give investors added comfort, OurCrowd vets every opportunity offered on its platform and selects only a small number, invests its own money in every deal, and co-investors often include many of the world’s leading VCs and institutions. By participating through OurCrowd, smaller investors can secure access to some of the best classes of shares, anti-dilution protection and other privileges usually reserved for major shareholders. “It can be difficult to get a clear picture of the current valuation of a private company when you are investing through secondary marketplaces. When you invest with OurCrowd you are joining a funding round alongside other very experienced dealmakers, reducing the risk of investing at an outsized price compared to the current company value,” Graston says. OurCrowd is not a passive investor. It takes an active role in helping the companies added to its portfolio to succeed, often taking a seat on the board and introducing them to potential partners, customers and future investors. Recently, OurCrowd extended its offering beyond VC funds to additional private market alternatives, including venture debt, private credit and private equity funds where the entry ticket can start at half a million dollars or more. OurCrowd makes funds from top-tier managers available to investors at much lower minimums, enabling many more people to participate in these opportunities. “The innovation wave, which is changing all of our lives – whether telemedicine or e-commerce or climate change – is going to be led by entrepreneurs who are backed by smart money and smart investors,” Medved says. “OurCrowd is where those entrepreneurs meet the smart money on a global basis, where they can work together to benefit everyone.” For more information about investing in startups with OurCrowd, click HERE. Featured photo courtesy of OurCrowd. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global ‘crowd’ gains access to VC-level investment opportunities.Today, OurCrowd is a global venture and alternative investing platform that empowers institutions and individuals to invest and engage in emerging companies. OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Lisa Graston lisa.graston@ourcrowd.com Company Website http://www.ourcrowd.com

May 03, 2024 09:00 AM Eastern Daylight Time

Image

5thScape to list its first game “MMA Cage Conquest” on Meta Store: Ultimate Virtual MMA Experience

Spark Metro PR

Mixed Martial Arts fans and enthusiasts, your virtual fighting dreams have arrived! 5th Scape delivers a transformative experience with "MMA Cage Conquest," stepping far beyond traditional fighting games into true sensory immersion. Step into the iconic MMA cage, feel the roar of the crowd and become the champion you always envisioned. The 5thScape Project is an ambitious venture that aims to create a comprehensive Virtual Reality ecosystem. In this VR ecosystem many developers, gamers and experts from various industries can collaborate. This is a VR gaming studio startup in which they focus on developing games, movies, animations etc. Apart from this, they are also planning to launch a special VR headset and a VR Chair which is an ergonomically perfect chair for long gaming sessions. Now, coming back to the game, - "MMA Cage Conquest" redefines virtual combat. Its skill-based system demands true martial arts strategy along with honed reflexes. Learn and master strikes like a real-life wrestling professional. It includes (not limited to) powerful grappling throws and the intricacies of ground control to secure your victories. Feel the impact of every blow, the thrill of a perfectly executed submission, and the tension of a match fought on the razor's edge. Training lies at the heart of "MMA Cage Conquest." This journey transcends button-mashing and enters the realm of personal development. Start as an eager underdog, mastering the fundamentals through rigorous simulations. Refine your striking, defense, and ground game, tracking your progression and building unshakeable confidence. With each session, you don't just play the game – you live the fight. MMA Cage Conquest is all set to make gaming experiences more vigorous and a powerhouse for the senses. Feel the rush in your bones as you climb the leaderboards, and establish yourself as the ultimate MMA cage conqueror. Ready to unleash your inner champion? " MMA Cage Conquest " will be available on the Meta platform. Submitted for listing on May 2, 2024, the developers await approval from Meta. Visit 5thscape.com for trailers, release updates, and the latest news on your journey to become the undisputed MMA Cage Conqueror. Contact Details 5th Scape 5thScape Team +1 302-597-6768 Team@5thscape.com Company Website https://5thscape.com

May 03, 2024 06:51 AM Eastern Daylight Time

Video Image

1 ... 34 35 36 37 38 ... 306